The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections
Status:
Withdrawn
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Participants are asked to be in this study because they have multiple sclerosis, are
currently treated with glatiramer acetate (GA, Copaxone®) injections and have redness, pain,
swelling, itching or a lump at the injection site.
The purpose of this study is to determine if the use of ethyl-a-guanida-methyl ethanoate
(AGEE) will decrease histamine response measured by redness, swelling, and itch response
following subcutaneous injection of glatiramer acetate (GA) for the treatment of Multiple
Sclerosis (MS).
Phase:
Phase 4
Details
Lead Sponsor:
University of Nebraska
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries